RTP Mobile Logo
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hodgkin and Non-Hodgkin Lymphomas (Webinar Audio Proceedings)
Released February 2023

Featuring perspectives from Drs Christopher Flowers and Laurie Sehn. Published February 17, 2023. (Webinar Audio Proceedings)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of Hodgkin and non-Hodgkin lymphomas.

    LEARNING OBJECTIVES

    • Understand published research informing the selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with previously untreated or relapsed/refractory (R/R) follicular lymphoma (FL).
    • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of diffuse large B-cell lymphoma (DLBCL) to determine the current and potential utility of those therapies in clinical practice.
    • Consider patient age, performance status and other clinical and biologic factors in the up-front and subsequent treatment of mantle cell lymphoma (MCL).
    • Incorporate available and emerging therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
    • Assess available clinical trial findings informing the use of CD19-directed CAR (chimeric antigen receptor) T-cell therapy for R/R DLBCL, MCL and FL, and counsel appropriately selected patients regarding the potential benefits of this strategy.
    • Recall new data with agents and strategies currently under investigation for HL and various forms of non-Hodgkin lymphoma, and consider the potential role of these agents in treatment regimens and ongoing trial opportunities for eligible patients.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Christopher R Flowers, MD, MS
    Chair, Professor
    Department of Lymphoma/Myeloma
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Celgene Corporation, Curio Science, Denovo Biopharma, Epizyme Inc, Foresight Diagnostics, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, MEI Pharma Inc, MorphoSys, Pharmacyclics LLC, an AbbVie Company, Seagen Inc; Research Funding: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptimmune, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Celgene Corporation, Cellectis, Eastern Cooperative Oncology Group, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, National Cancer Institute, Nektar, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, The V Foundation for Cancer Research, Xencor, ZIOPHARM Oncology Inc.

    Laurie H Sehn, MD, MPH
    Chair, Lymphoma Tumour Group
    BC Cancer Centre for Lymphoid Cancer
    Clinical Professor of Medicine
    Division of Medical Oncology
    University of British Columbia
    Associate Editor, Blood
    Vancouver, British Columbia, Canada

    Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Seagen Inc, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Contracted Research: Genentech, a member of the Roche Group, Teva Oncology.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, GSK, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Incyte Corporation, Karyopharm Therapeutics, and Seagen Inc.

    Release date: February 2023
    Expiration date: February 2024

Acknowledge and close

Listen to audio
(WIFI is recommended for best performance):